Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RO5545965 + risperidone
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
RO5545965 + risperidone is a combination therapy investigated for the treatment of schizophrenia. **RO5545965** is a phosphodiesterase 10A (PDE10A) inhibitor developed to modulate dopaminergic and glutamatergic signaling through inhibition of PDE10A, an enzyme highly expressed in the striatum. **Risperidone** is a second-generation antipsychotic that acts primarily as an antagonist at dopamine D2 and serotonin 5-HT2A receptors, reducing dopaminergic and serotonergic signaling implicated in schizophrenia[1][4][2].
02
Targets
DRD4 (Dopamine D4 Receptor)HTR2A (Serotonin receptor 5-HT2A)ADRA2A (α2A)HTR2C (5-hydroxytryptamine 2C receptor)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HRH1 (Histamine H1 Receptor)DRD1 (Dopamine D1 Receptor)ADRA1A (α1A)DRD2 (Dopamine D2 Receptor)PDE10A (Phosphodiesterase 10A)
Beyond the preview
Go deeper on RO5545965 + risperidone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RO5545965 + risperidone.